Methods and uses for recurrent primary CNS tumors

The present disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment at least a first therapeutic agent comprising ONC-206, 7-benzyl-4-(2, 4-difluorobenzyl)-2, 4, 6, 7, 8, 9-hexahydroimid...

Full description

Saved in:
Bibliographic Details
Main Authors LEE ANTHONY KWO-KEUNG, ALLEN JOSHUA E, PRABHU VARUN VIJAY, CHAPPELL, JOHN, C, SETHNER, PAUL, B, NADLER OLIVER JAMES
Format Patent
LanguageChinese
English
Published 20.02.2024
Subjects
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment at least a first therapeutic agent comprising ONC-206, 7-benzyl-4-(2, 4-difluorobenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1, 2-a] pyrido [3, 4-e] pyrimidine-5 (1H)-one for the treatment of one or more CNS tumors. 本公开至少部分地涉及一种治疗的方法。在一个实施方案中,所述治疗的方法包括向有此类治疗需要的受试者施用至少第一治疗剂,所述第一治疗剂包含ONC-206,7-苄基-4-(2,4-二氟苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮,用于治疗一种或多种CNS肿瘤。
Bibliography:Application Number: CN20228046344